statistics in biomedical research rise program 2011 los angeles biomedical research institute at...

59
Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Upload: angelina-bridges

Post on 05-Jan-2016

217 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Statistics in Biomedical Research

RISE Program 2011

Los Angeles Biomedical Research Institute

at Harbor-UCLA Medical Center

January 13, 2011

Peter D. Christenson

Page 2: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Scientific Decision Making

Setting:

Two groups of animals: one gets a new molecule you have created, the other group doesn't.

Measure the relevant outcome in all animals.

How do we decide if the molecule has an effect?

Page 3: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Balancing Risk: Business

You have a vending machine business.

The machines have a dollar bill reader.

You can set the reader to be loose or strict.

Setting too high → rejects valid bills, loses customers.

Setting too low → accepts bogus bills, you lose.

Need to balance both errors in some way.

Page 4: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Balancing Risk: U.S. Legal System

Need to decide guilty or innocent.

Jury or judge measures degree of guilt.

Civil case: lower degree needed than legal case.

Setting degree high → frees suspects who are guilty.

Setting degree low → jails suspects who are innocent.

Need to balance both errors in some way.

Page 5: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Balancing Risk: Personal

Investments have expected returns of 1% to 20%.

As expected returns ↑, the chances they don’t ↑.

You choose your degree of risk.

Setting degree high → chances of losing ↑.

Setting degree low → chances of missing big $ ↑.

Need to balance both errors in some way.

Page 6: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Balancing Risk: Scientific Research

Perform experiment on 20 mice to measure an effect.

Only 20 mice may not be representative.

Need to decide if effect is real or random.

You choose a minimal degree of effect → Call real.

Setting degree high → chances* of missing effect ↑.

Setting degree low → chances** of wrong + result ↑.

Need to balance both errors in some way.

What would you want chances for * and for ** to be?

Page 7: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Scientific Decision MakingSetting: Two groups, one gets drug A, one gets placebo (B). Measure outcome.

Subjects may respond very differently.

How do we decide if the drug has “an effect”?

Perhaps: Say yes if the mean outcome of those receiving drug is greater than the mean of the others? Or twice as great? Or the worst responder on drug was better than the best on placebo? Other?

Page 8: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Meaning or Randomness?

Page 9: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Meaning or Randomness?

This is the goal of science in general.

The role of statistics is to give an objective way to make those decisions.

Page 10: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Meaning or Randomness?

Scientific inference: Perform experiment.

Make a decision: Is it real or random?

Quantify chances that our decision is correct or not.

Other areas of life:

Suspect guilty? Nobel laureate's opinion?

Make a decision: Is it real or random?

Usually cannot quantify.

Page 11: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Specialness of Scientific ResearchScientific method:

Assume the opposite of what we think.

Design the experiment so that our opinions cannot influence the outcome.

Say exactly how we will make a conclusion, i.e. making a decision from the experiment.

Tie our hands behind our back. Do experiment.

Make decision. Find the chances (from calculations, not opinion) that we are wrong.

Experimental conclusions are not expert opinion.

Page 12: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making

We first discuss using a medical device to make decisions about a patient.

These decisions could be right or wrong.

We then make an analogy to using an experiment to make decisions about a scientific question.

These decisions could be right or wrong.

Page 13: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making

The next eight slides will make an analogy to how conclusions or decisions from

experiments are made.

The numbers are made-up.

Mammograms are really better than this.

Page 14: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making: Diagnosis

Mammogram Spot Darkness 100

Definitely Not Cancer

Definitely Cancer

How is the decision made for intermediate darkness?

A particular woman with cancer may not have a 10. Another woman without cancer may not have 0.

Page 15: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Need graph here of the overlap in the CA and non-CA groups.

It needs to correspond to the %s in the next few slides.

Page 16: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making: Diagnosis

Mammogram Spot Darkness100

Suppose a study found the mammogram rating (0-10) for 1000 women who definitely have cancer by biopsy (truth).

Proportion of 1000 Women:1000/1000

0/1000

100/1000600/1000

900/1000990/1000

2 4 6 8

Use What Cutoff?

Page 17: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making: Sensitivity

Cutoff for Spot Darkness Mammogram Sensitivity

≥0 100%

>2 99%

>4 90%

>6 60%

>8 10%

>10 0%

Sensitivity = Chances of correctly detecting disease.

Why not just choose a low cutoff and detect almost everyone with disease?

Page 18: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making Continued

Mammogram Spot Darkness100

Suppose a study found the mammogram rating (0-10) for 1000 women who definitely do NOT have cancer by biopsy (truth).

Proportion of 1000 Women: 1000/1000

0/1000

350/1000700/1000

900/1000950/1000

2 4 6 8

Use What Cutoff?

Page 19: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making: Specificity

Cutoff for Spot Darkness Mammogram Specificity

<0 0%

≤2 35%

≤4 70%

≤6 90%

≤8 95%

≤10 100%

Specificity=Chances of correctly NOT detecting disease.

Page 20: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making: Tradeoff

Cutoff Sensitivity Specificity

0 100% 0%

2 99% 35%

4 90% 70%

6 60% 90%

8 10% 95%

10 0% 100%

Choice of cutoff depends on whether the diagnosis is a screening or a final one. For example:

Cutoff=4 : Call disease in 90% with it and 30% without.

Page 21: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Make Decision: If Spot>6, Decide CA. If Spot≤6, Decide Not CA.

True Non-CA Patients

True CA Patients

Mammogram Spot Darkness0 2 4 6 8 10

\\\ = Specificity = 90%.

/// = Sensitivity = 60%.

Graphical Representation of Tradeoffs

Area under curve =

Probability

# of women

90% 60%

cutoffDecide A=B Decide A≠B

Page 22: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

95%

10%

Tradeoffs From a Stricter Cutoff

cutoff

0 2 4 6 8 10

Mammogram Spot Darkness

Decide A=B Decide A≠B

Page 23: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making for Diagnosis: Summary

As sensitivity increases, specificity decreases and vice-versa.

Cannot increase both sensitivity and specificity together.

We now develop sensitivity and specificity to test or decide scientific claims. Analogy:

True Disease ↔ True claim, real effect.

Decide Disease ↔ Decide effect is real.

But, can both increase sensitivity and specificity together.

Page 24: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Decision Making

End of analogy.

Back to our original problem in experiments.

Page 25: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Scientific Decision Making

Setting: Two groups, one gets drug A, one gets placebo (B). Measure outcome.

Subjects may respond very differently.

How do we decide if the drug has “an effect”?

Perhaps: Say yes if the mean outcome of those receiving drug is greater than the mean of the others? Or twice as great? Or the worst responder on drug was better than the best on placebo? Other?

Page 26: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Scientific Decision Making

Setting: Two groups, one gets drug A, one gets placebo (B). Measure outcome.

How do we decide if the drug has an effect?

Perhaps: Say yes if the mean of those receiving drug is greater than the mean of the placebo group? Other decision rules?

Let’s just try an arbitrary decision rule:

Let Δ = Group A Mean minus Group B Mean

Decide that A>B if Δ>2. [Not just Δ>2.]

Page 27: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Make Decision: If Δ>2, then Decide A≠B. If Δ≤2, then Decide A=B.

True No Effect (A=B)

True Effect (A≈B+2.2)

Eventual Graphical Representation

1. Where do these curves come from?

2. What are the consequences of using cutoff=2?

Δ = Group A Mean minus Group B Mean -2 0 2 4 6

90% 60%

Decide A=B Decide A≠B

Page 28: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Question 2 First

2. What are the consequences of using cutoff=2?

Answer:

If the effect is real (A≠B), there is a 60% chance of deciding so. [Actually, if in particular A is 2.2 more than B.] This is the experiment’s sensitivity, more often called power.

If effect is not real (A=B), there is a 90% of deciding so. This is the experiment’s specificity. More often, 100-specificity is called the level of significance.

Page 29: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Question 2 ContinuedWhat if cutoff=1 was used instead?

If the effect is real (Δ=A-B=2.2), there is about a 85% chance of deciding so. Sensitivity ↑ (from 60%).

If effect is not real (Δ=A-B=0), there is about a 60% of deciding so. Specificity ↓ (from about 90%).

Δ: 0 1 2.2

60%85%

Page 30: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Typical Choice of Cutoff

Δ = Group A Mean minus Group B Mean -2 0 2 4 6

Require specificity to be 95%. This means there is only a 5% chance of wrongly declaring an effect. → Need overwhelming evidence, beyond a reasonable (5%) doubt, to make a claim.

~45% Power

95% Specificity

Page 31: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Strength of the Scientific MethodScientists (and their journals and FDA) require overwhelming evidence, beyond a reasonable (5%) doubt, not just “preponderance of the truth” which would be specificity=50%.

Similar to US court of law. So much stronger than expert opinion.

~45% Power

Only 5% chance of a false positive claim

How can we increase power above this 45%, but maintain the chances of a false positive conclusion at ≤5%?

Are we just stuck with knowing that many true conjectures will be thrown away as collateral damage to this rigor?

Page 32: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

How to Increase Power

How can we increase power above this 45%, but maintain the chances of a false positive conclusion at ≤5%?

Are we just stuck with knowing that many true conjectures will be thrown away as collateral damage to this rigor?

To answer this, we need to go into how the curves are made:

So, we take a detour for the next 8 slides to show this.

Page 33: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Back to Question 1

1. Where do the curves in the last figure come from?

Answer:

You specify three quantities: (1) where their peaks are (the experiment’s detectable difference), and how wide they are (which is determined by (2) natural variation and (3) the # of subjects or animals or tissue samples, N).

Those specifications give a unique set of “bell-shaped” curves. How?

Page 34: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

A “Law of Large Numbers”

Suppose individuals have values ranging from Lo to Hi, but the % with any particular value could be anything, say:

You choose a sample of 2 of these individuals, and find their average. What value do you expect the average to have?

Lo LoHi Hi

Prob ↑

N = 1

Page 35: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

A “Law of Large Numbers”

In both cases, values near the center will be more likely:

Now choose a sample of 4 of these individuals, and find their average. What value do you expect the average to have?

Lo LoHi Hi

Prob ↑

N = 2

Page 36: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

A “Law of Large Numbers”

In both cases, values near the center will be more likely:

Now choose a sample of 10 of these individuals, and find their average. What value do you expect the average to have?

Lo LoHi Hi

Prob ↑

N = 4

Page 37: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

A “Law of Large Numbers”

In both cases, values near the center will be more likely:

Now choose a sample of 50 of these individuals, and find their average. What value do you expect the average to have?

Lo LoHi Hi

Prob ↑

N = 10

Page 38: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

A “Law of Large Numbers”

In both cases, values near the center will be more likely:

A remarkable fact is that not only is the mean of the sample is expected to be close to the mean of “everyone” if N is large enough, but we know exact probabilities of how close, and the shape of the curve.

Lo LoHi Hi

Prob ↑

N = 50

Page 39: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Summary: Law of Large Numbers

Lo LoHi Hi

Prob ↑

N = 1

SD↔ ↔SD

Lo Value of the mean of N subjects Hi↔

SD(Mean) = SD/√N

SD is about 1/6 of the total range.

SD ≈ 1.25 x average deviation from the center.

Large N

Page 40: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Law of Large Numbers: Another View

rescaled

You can make the range of possible values for a mean as small as you like by choosing a large enough sample.

Also the shape will always be a bell curve if the sample is large enough.

Page 41: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Scientific Decision Making

So, where are we?

We can now answer the basic dilemma we raised.

Repeat earlier slide:

Page 42: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Strength of the Scientific MethodScientists (and their journals and FDA) require overwhelming evidence, beyond a reasonable (5%) doubt, not just “preponderance of the truth” which would be specificity=50%.

Similar to US court of law. So much stronger than expert opinion.

~45% Power

Only 5% chance of a false positive claim

How can we increase power, but maintain the chances of a false positive conclusion at ≤5%?

Are we just stuck with knowing that many true conjectures will be thrown away as collateral damage to this rigor?

N = 50

Page 43: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Scientific Decision Making

So, the answer is that by choosing N large enough, the mean has to be in a small range.

That narrow the curves.

That in turn increases the chances that we will find the effect in our study, i.e., its power.

The next slide shows this.

Page 44: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Fix the max chances of a false positive claim at 5%

80% Power

N = 75

N = 50

95% 45%

95%

95%

N = 88

74%

80%

74% Power

45% Power

Find N that gives the power you want.

Page 45: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

In many experiments, five factors are inter-related. Specifying four of these determines the fifth:

1. Study size, N.

2. Power, usually 80% to 90% is used.

3. Acceptable false positive chance, usually 5%.

4. Magnitude of the effect to be detected (Δ).

5. Heterogeneity among subjects or units (SD).

The next 2 slides show how these factors are typically examined, and easy software to do the calculations.

Putting it All Together

Page 46: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Quote from An LA BioMed ProtocolThe following table presents detectable differences, with p=0.05 and 80% power, for different study sizes.

Total Number

of Subjects

Detectable Difference in

Change in Mean MAP (mm Hg)(1)

Detectable Difference in

Change in Mean Number

of Vasopressors(2)

20 10.9 0.77 40 7.4 0.49 60 6.0 0.39 80 5.2 0.34 100 4.6 0.30 120 4.2 0.27

Thus, with a total of the planned 80 subjects, we are 80% sure to detect (p<0.05) group differences if treatments actually differ by at least 5.2 mm Hg in MAP change, or by a mean 0.34 change in number of vasopressors.

Page 47: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Software for Previous SlidePilot data: SD=8.19 for ΔMAP in 36 subjects.

For p-value<0.05, power=80%, N=40/group, the detectable Δ of 5.2 in the previous table is found as:

Page 48: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Study Size : May Not be Based on Power

Precision refers to how well a measure is estimated.

Margin of error = the ± value (half-width) of the 95% confidence interval (sorry – not discussed here).

Smaller margin of error ←→ greater precision.

To achieve a specified margin of error, solve the CI formula for N.Polls: N ≈ 1000→ margin of error on % ≈ 1/√N ≈ 3%.

Pilot Studies, Phase I, Some Phase II: Power not relevant; may have a goal of obtaining an SD for future studies.

Page 49: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Study Design Considerations Statistical Components of Protocols

• Target population / source of subjects.• Quantification of aims, hypotheses.• Case definitions, endpoints quantified. • Randomization plan, if one will be used.• Masking, if used.• Study size: screen, enroll, complete.• Use of data from non-completers.• Justification of study size (power, precision, other).• Methods of analysis.• Mid-study analyses.

Page 50: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Resources, Software, and References

Page 51: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Professional Statistics Software Package

Output

Enter code; syntax.

Stored data; access-ible.

Comprehensive, but steep learning curve: SAS, SPSS, Stata.

Page 52: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Microsoft Excel for Statistics

• Primarily for descriptive statistics.

• Limited output.

Page 53: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Typical Statistics Software PackageSelect Methods from Menus

Output after menu selection

Data in spreadsheet

www.ncss.com

www.minitab.com

www.stata.com

$100 - $500

Page 54: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Free Statistics Software: Mystatwww.systat.com

Page 55: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Free Study Size Software

www.stat.uiowa.edu/~rlenth/Power

Page 56: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

http://gcrc.labiomed.org/biostat

This and

other biostat talks

posted

Page 57: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Recommended Textbook: Making Inference

Design issues

Biases

How to read papers

Meta-analyses

Dropouts

Non-mathematical

Many examples

Page 58: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Thank You

Nils Simonson, in

Furberg & Furberg,

Evaluating Clinical Research

Page 59: Statistics in Biomedical Research RISE Program 2011 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center January 13, 2011 Peter D. Christenson

Outline

Meaning or randomness?

Decisions, truth and errors.

Sensitivity and specificity.

Laws of large numbers.

Experiment size and study power.

Study design considerations.

Resources, software, and references.